Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 6, 2013, Pages 3696-3710

  Faridi, Mohd Hafeez ^a   Altintas, Mehmet M ^a   Gomez, Camilo ^a   Duque, Juan Camilo ^a   Vazquez Padron, Roberto I ^a   Gupta, Vineet ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti adhesion therapy; CD11b CD18; Cell adhesion; Drug discovery; Inflammation; Leukocyte

Indexed keywords

ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CD18 ANTIGEN; IMMUNOGLOBULIN G1; INTEGRIN; LEUKADHERIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ED7; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD VESSEL INJURY; CELL ADHESION; CELL MIGRATION; CELL SURFACE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WOUND HEALING;

ALLOSTERIC REGULATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD11B; ANTIGENS, CD18; CELL ADHESION; HUMANS; ILIAC ARTERY; INFLAMMATION; K562 CELLS; MICE; PROTEIN STRUCTURE, QUATERNARY; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; WOUND HEALING;

ANIMALIA;

EID: 84875982052     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.02.018     Document Type: Article

References (88)

1. R.O. Hynes Integrins: bidirectional, allosteric signaling machines Cell 110 2002 673 687
2. -/-) mice reveals a role for inflammation in vascular repair after angioplasty J. Clin. Invest. 105 2000 293 300
3. M.A. Arnaout, R.F. Todd III, N. Dana, J. Melamed, S.F. Schlossman, and H.R. Colten Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol) J. Clin. Invest. 72 1983 171 179
4. R. Li, and M.A. Arnaout Functional analysis of the beta 2 integrins Methods Mol. Biol. 129 1999 105 124
5. P. Rieu, T. Sugimori, D.L. Griffith, and M.A. Arnaout Solvent-accessible residues on the metal ion-dependent adhesion site face of integrin CR3 mediate its binding to the neutrophil inhibitory factor J. Biol. Chem. 271 1996 15858 15861
6. K. Yonekawa, and J.M. Harlan Targeting leukocyte integrins in human diseases J. Leukoc. Biol. 77 2005 129 140
7. M. Shimaoka, and T.A. Springer Therapeutic antagonists and conformational regulation of integrin function Nat. Rev. Drug Discov. 2 2003 703 716
8. J.M. Harlan, and R.K. Winn Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy Crit. Care Med. 30 2002 S214 S219
9. D. Cox, M. Brennan, and N. Moran Integrins as therapeutic targets: lessons and opportunities Nat. Rev. Drug Discov. 9 2010 804 820
10. A. Dove CD18 trials disappoint again Nat. Biotechnol. 18 2000 817 818
11. E.S. Molloy, and L.H. Calabrese Therapy: targeted but not trouble-free: efalizumab and PML Nat. Rev. Rheumatol. 5 2009 418 419
12. D. Maiguel, M.H. Faridi, C. Wei, Y. Kuwano, K.M. Balla, D. Hernandez, C.J. Barth, G. Lugo, M. Donnelly, A. Nayer, L.F. Moita, S. Schurer, D. Traver, P. Ruiz, R.I. Vazquez-Padron, K. Ley, J. Reiser, and V. Gupta Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease Sci. Signal. 4 2011 ra57
13. M.A. Arnaout Integrin structure: new twists and turns in dynamic cell adhesion Immunol. Rev. 186 2002 125 140
14. J. Stockl, O. Majdic, W.F. Pickl, A. Rosenkranz, E. Prager, E. Gschwantler, and W. Knapp Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 alpha-chain (CD11b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol- anchored Fc gamma RIIIB (CD16) molecules J. Immunol. 154 1995 5452 5463
15. C. Lu, M. Ferzly, J. Takagi, and T.A. Springer Epitope mapping of antibodies to the C-terminal region of the integrin beta 2 subunit reveals regions that become exposed upon receptor activation J. Immunol. 166 2001 5629 5637
16. L. Petruzzelli, L. Maduzia, and T.A. Springer Activation of lymphocyte function-associated molecule-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) mimicked by an antibody directed against CD18 J. Immunol. 155 1995 854 866
17. 2 + binding epitope on leukocyte integrin alpha subunits EMBO J. 8 1989 3759 3765
18. D. Andrew, A. Shock, E. Ball, S. Ortlepp, J. Bell, and M. Robinson KIM185, a monoclonal antibody to CD18 which induces a change in the conformation of CD18 and promotes both LFA-1- and CR3-dependent adhesion Eur. J. Immunol. 23 1993 2217 2222
19. P. Stephens, J.T. Romer, M. Spitali, A. Shock, S. Ortlepp, C.G. Figdor, and M.K. Robinson KIM127, an antibody that promotes adhesion, maps to a region of CD18 that includes cysteine-rich repeats Cell Adhes. Commun. 3 1995 375 384
20. R.P. Orchekowski, J. Plescia, D.C. Altieri, and M.L. Bajt AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive J. Leukoc. Biol. 68 2000 641 649
21. C.R. Beals, A.C. Edwards, R.J. Gottschalk, T.W. Kuijpers, and D.E. Staunton CD18 activation epitopes induced by leukocyte activation J. Immunol. 167 2001 6113 6122
22. J.R. Huth, E.T. Olejniczak, R. Mendoza, H. Liang, E.A. Harris, M.L. Lupher Jr., A.E. Wilson, S.W. Fesik, and D.E. Staunton NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding Proc. Natl. Acad. Sci. U. S. A. 97 2000 5231 5236
23. H. Zhang, J.H. Liu, W. Yang, T. Springer, M. Shimaoka, and J.H. Wang Structural basis of activation-dependent binding of ligand-mimetic antibody AL-57 to integrin LFA-1 Proc. Natl. Acad. Sci. U. S. A. 106 2009 18345 18350
24. S. Ortlepp, P.E. Stephens, N. Hogg, C.G. Figdor, and M.K. Robinson Antibodies that activate beta 2 integrins can generate different ligand binding states Eur. J. Immunol. 25 1995 637 643
25. F. Sanchez-Madrid, P. Simon, S. Thompson, and T.A. Springer Mapping of antigenic and functional epitopes on the alpha- and beta-subunits of two related mouse glycoproteins involved in cell interactions, LFA-1 and Mac-1 J. Exp. Med. 158 1983 586 602
26. A.A. Sharfuddin, and B.A. Molitoris Pathophysiology of ischemic acute kidney injury Nat. Rev. Nephrol. 7 2011 189 200
27. G. Varga, S. Balkow, M.K. Wild, A. Stadtbaeumer, M. Krummen, T. Rothoeft, T. Higuchi, S. Beissert, K. Wethmar, K. Scharffetter-Kochanek, D. Vestweber, and S. Grabbe Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation Blood 109 2007 661 669
28. B. Draskovic-Pavlovic, L.J. Van Der Laan, N. Pejnovic, C.D. Dijkstra, and M. Colic Differential effects of anti-rat CD11b monoclonal antibodies on granulocyte adhesiveness Immunology 96 1999 83 89
29. C.T. Lefort, Y.M. Hyun, J.B. Schultz, F.Y. Law, R.E. Waugh, P.A. Knauf, and M. Kim Outside-in signal transmission by conformational changes in integrin Mac-1 J. Immunol. 183 2009 6460 6468
30. E. Pluskota, D.A. Soloviev, D. Szpak, C. Weber, and E.F. Plow Neutrophil apoptosis: selective regulation by different ligands of integrin alphaMbeta2 J. Immunol. 181 2008 3609 3619
31. B.B. Whitlock, S. Gardai, V. Fadok, D. Bratton, and P.M. Henson Differential roles for alpha(M)beta(2) integrin clustering or activation in the control of apoptosis via regulation of akt and ERK survival mechanisms J. Cell Biol. 151 2000 1305 1320
32. S.D. Wright, P.E. Rao, W.C. Van Voorhis, L.S. Craigmyle, K. Iida, M.A. Talle, E.F. Westberg, G. Goldstein, and S.C. Silverstein Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies Proc. Natl. Acad. Sci. U. S. A. 80 1983 5699 5703
33. N. Hogg, M.P. Stewart, S.L. Scarth, R. Newton, J.M. Shaw, S.K. Law, and N. Klein A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1 J. Clin. Invest. 103 1999 97 106
34. J.G. Damoiseaux, E.A. Dopp, J.J. Neefjes, R.H. Beelen, and C.D. Dijkstra Heterogeneity of macrophages in the rat evidenced by variability in determinants: two new anti-rat macrophage antibodies against a heterodimer of 160 and 95 kd (CD11/CD18) J. Leukoc. Biol. 46 1989 556 564
35. A.P. Robinson, T.M. White, and D.W. Mason Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3 Immunology 57 1986 239 247
36. T. Springer, G. Galfre, D.S. Secher, and C. Milstein Mac-1: a macrophage differentiation antigen identified by monoclonal antibody Eur. J. Immunol. 9 1979 301 306
37. J.Y. Park, M.A. Arnaout, and V. Gupta A simple, no-wash cell adhesion-based high-throughput assay for the discovery of small-molecule regulators of the integrin CD11b/CD18 J. Biomol. Screen. 12 2007 406 417
38. V. Gupta, A. Gylling, J.L. Alonso, T. Sugimori, P. Ianakiev, J.P. Xiong, and M.A. Arnaout The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin CD11b/CD18 Blood 109 2007 3513 3520
39. K. Szczur, Y. Zheng, and M.D. Filippi The small Rho GTPase Cdc42 regulates neutrophil polarity via CD11b integrin signaling Blood 114 2009 4527 4537
40. J.P. Xiong, T. Stehle, S.L. Goodman, and M.A. Arnaout New insights into the structural basis of integrin activation Blood 102 2003 1155 1159
41. E.E. Gabeler, R. van Hillegersberg, R.G. Statius van Eps, W. Sluiter, E.J. Gussenhoven, P. Mulder, and H. van Urk A comparison of balloon injury models of endovascular lesions in rat arteries BMC Cardiovasc. Disord. 2 2002 16
42. M.H. Faridi, D. Maiguel, C.J. Barth, D. Stoub, R. Day, S. Schurer, and V. Gupta Identification of novel agonists of the integrin CD11b/CD18 Bioorg. Med. Chem. Lett. 19 2009 6902 6906
43. N. Nishida, C. Xie, M. Shimaoka, Y. Cheng, T. Walz, and T.A. Springer Activation of leukocyte beta(2) integrins by conversion from bent to extended conformations Immunity 25 2006 583 594
44. D.C. Altieri Occupancy of CD11b/CD18 (Mac-1) divalent ion binding site(s) induces leukocyte adhesion J. Immunol. 147 1991 1891 1898
45. I. Dransfield, C. Cabanas, A. Craig, and N. Hogg Divalent cation regulation of the function of the leukocyte integrin LFA-1 J. Cell Biol. 116 1992 219 226
46. J.P. Xiong, R. Li, M. Essafi, T. Stehle, and M.A. Arnaout An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain J. Biol. Chem. 275 2000 38762 38767
47. G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat. Med. 7 2001 687 692
48. G. Weitz-Schmidt, K. Welzenbach, J. Dawson, and J. Kallen Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by X-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo J. Biol. Chem. 279 2004 46764 46771
49. J.C. Yarrow, Z.E. Perlman, N.J. Westwood, and T.J. Mitchison A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods BMC Biotechnol. 4 2004 21
50. M.G. Lampugnani Cell migration into a wounded area in vitro Meth. Mol. Biol. (Clifton, N.J.) 96 1999 177 182
51. P. Martin, and S.J. Leibovich Inflammatory cells during wound repair: the good, the bad and the ugly Trends Cell Biol. 15 2005 599 607
52. T. Lammermann, B.L. Bader, S.J. Monkley, T. Worbs, R. Wedlich-Soldner, K. Hirsch, M. Keller, R. Forster, D.R. Critchley, R. Fassler, and M. Sixt Rapid leukocyte migration by integrin-independent flowing and squeezing Nature 453 2008 51 55
53. P.W. Suen, D. Ilic, E. Caveggion, G. Berton, C.H. Damsky, and C.A. Lowell Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages J. Cell Sci. 112 Pt 22 1999 4067 4078
54. G.C. Alghisi, L. Ponsonnet, and C. Ruegg The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells PLoS One 4 2009 e4449
55. D. Cox Oral GPIIb/IIIa antagonists: what went wrong? Curr. Pharm. Des. 10 2004 1587 1596
56. K. Peter, M. Schwarz, J. Ylanne, B. Kohler, M. Moser, T. Nordt, P. Salbach, W. Kubler, and C. Bode Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors Blood 92 1998 3240 3249
57. 2 + ion at the metal ion-dependent adhesion site in integrin CD11b/CD18 by an antibody-derived ligand aspartate: implications for integrin regulation and structure-based drug design J. Immunol. 187 2011 6393 6401
58. J. Zhu, A. Negri, D. Provasi, M. Filizola, B.S. Coller, and T.A. Springer Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening Blood 116 2010 5050 5059
59. D.P. Chew, D.L. Bhatt, S. Sapp, and E.J. Topol Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials Circulation 103 2001 201 206
60. C. Gao, B. Boylan, D. Bougie, J.C. Gill, J. Birenbaum, D.K. Newman, R.H. Aster, and P.J. Newman Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain J. Clin. Invest. 119 2009 504 511
61. F.G. Giancotti, and E. Ruoslahti Integrin signaling Science 285 1999 1028 1032
62. 2 +)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion J. Biol. Chem. 277 2002 29468 29476
63. R. Kettritz, M. Choi, S. Rolle, M. Wellner, and F.C. Luft Integrins and cytokines activate nuclear transcription factor-kappaB in human neutrophils J. Biol. Chem. 279 2004 2657 2665
64. R. Rezzonico, V. Imbert, R. Chicheportiche, and J.M. Dayer Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB Blood 97 2001 2932 2940
65. B. Walzog, P. Weinmann, F. Jeblonski, K. Scharffetter-Kochanek, K. Bommert, and P. Gaehtgens A role for beta(2) integrins (CD11/CD18) in the regulation of cytokine gene expression of polymorphonuclear neutrophils during the inflammatory response FASEB J. 13 1999 1855 1865
66. G.L. Johnson, and R. Lapadat Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 298 2002 1911 1912
67. H. Yu, S.J. Suchard, R. Nairn, and R. Jove Dissociation of mitogen-activated protein kinase activation from the oxidative burst in differentiated HL-60 cells and human neutrophils J. Biol. Chem. 270 1995 15719 15724
68. M. Semmrich, A. Smith, C. Feterowski, S. Beer, B. Engelhardt, D.H. Busch, B. Bartsch, M. Laschinger, N. Hogg, K. Pfeffer, and B. Holzmann Importance of integrin LFA-1 deactivation for the generation of immune responses J. Exp. Med. 201 2005 1987 1998
69. E.J. Park, J.R. Mora, C.V. Carman, J. Chen, Y. Sasaki, G. Cheng, U.H. von Andrian, and M. Shimaoka Aberrant activation of integrin alpha4beta7 suppresses lymphocyte migration to the gut J. Clin. Invest. 117 2007 2526 2538
70. E.J. Park, A. Peixoto, Y. Imai, A. Goodarzi, G. Cheng, C.V. Carman, U.H. von Andrian, and M. Shimaoka Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes Blood 115 2010 1572 1581
71. M. Kim, C.V. Carman, and T.A. Springer Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins Science 301 2003 1720 1725
72. K.T. Stroupe, D.A. Morrison, M.A. Hlatky, P.G. Barnett, L. Cao, C. Lyttle, D.M. Hynes, and W.G. Henderson Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients Circulation 114 2006 1251 1257
73. A.E. Ajani, B.P. Yan, D.J. Clark, D. Eccleston, A. Walton, R. Lew, A. Meehan, A. Brennan, C. Reid, and S.J. Duffy Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents Heart Lung Circ. 16 2007 269 273
74. M. Chen, J. John, D. Derek, D. Lee, S. Ellis, and D. Bhatt Bare metal stent restenosis is not a benign clinical entity Am. Heart J. 151 2006 1260 1264
75. A. Kaltoft, H. Kelbaek, L. Thuesen, J.F. Lassen, P. Clemmensen, L. Klovgaard, T. Engstrom, H.E. Botker, K. Saunamaki, L.R. Krusell, E. Jorgensen, H.H. Tilsted, E.H. Christiansen, J. Ravkilde, L. Kober, K.F. Kofoed, C.J. Terkelsen, and S. Helqvist Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial J. Am. Coll. Cardiol. 56 2010 641 645
76. Y. Wang, M. Sakuma, Z. Chen, V. Ustinov, C. Shi, K. Croce, A.C. Zago, J. Lopez, P. Andre, E. Plow, and D.I. Simon Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury Circulation 112 2005 2993 3000
77. C. Rogers, E.R. Edelman, and D.I. Simon A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits Proc. Natl. Acad. Sci. U. S. A. 95 1998 10134 10139
78. Y. Wang, D. Mahajan, Y.C. Tay, S. Bao, T. Spicer, L. Kairaitis, G.K. Rangan, and D.C. Harris Partial depletion of macrophages by ED7 reduces renal injury in adriamycin nephropathy Nephrology (Carlton) 10 2005 470 477
79. M.J. Palmen, C.D. Dijkstra, M.B. van der Ende, A.S. Pena, and E.P. van Rees Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats Clin. Exp. Immunol. 101 1995 351 356
80. J.G. Damoiseaux, E.A. Döpp, J.J. Neefjes, R.H. Beelen, and C.D. Dijkstra Heterogeneity of macrophages in the rat evidenced by variability in determinants: two new anti-rat macrophage antibodies against a heterodimer of 160 and 95 kd (CD11/CD18) J. Leukoc. Biol. 46 1989 556 564
81. I. Huitinga, J.G. Damoiseaux, E.A. Dopp, and C.D. Dijkstra Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats Eur. J. Immunol. 23 1993 709 715
82. M.J. Quinn, E.F. Plow, and E.J. Topol Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 106 2002 379 385
83. V.K. Lishko, B. Kudryk, V.P. Yakubenko, V.C. Yee, and T.P. Ugarova Regulated unmasking of the cryptic binding site for integrin alpha M beta 2 in the gamma C-domain of fibrinogen Biochemistry 41 2002 12942 12951
84. M.J. Flick, X. Du, and J.L. Degen Fibrin(ogen)-alpha M beta 2 interactions regulate leukocyte function and innate immunity in vivo Exp. Biol. Med. (Maywood) 229 2004 1105 1110
85. M.J. Flick, X. Du, D.P. Witte, M. Jirouskova, D.A. Soloviev, S.J. Busuttil, E.F. Plow, and J.L. Degen Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo J. Clin. Invest. 113 2004 1596 1606
86. T. Schurpf, and T.A. Springer Regulation of integrin affinity on cell surfaces EMBO J. 30 2011 4712 4727
87. G.O. Ahn, D. Tseng, C.H. Liao, M.J. Dorie, A. Czechowicz, and J.M. Brown Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment Proc. Natl. Acad. Sci. U. S. A. 107 2010 8363 8368
88. J.O. Lee, L.A. Bankston, M.A. Arnaout, and R.C. Liddington Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure 3 1995 1333 1340